- Ultragenyx Pharmaceutical (NASDAQ:RARE) preliminary full-year 2019 total revenue of $102M-$104M exceeds the average analyst estimate of $100.0M.
- More news on: Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
Market:
Ultragenyx Pharmaceutical Inc. Website:
2024-03-18 11:30:02 ET Wedbush analyst issues BUY recommendation for RARE on March 18, 2024 09:00AM ET. The previous analyst recommendation was Buy. RARE was trading at $47.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
44th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26th Annual Global Healthcare...
44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceut...